MONISTAT 7 Drug Patent Profile

Which patents cover Monistat 7, and when can generic versions of Monistat 7 launch?

Monistat 7 is a drug marketed by Medtech Products and is included in three NDAs.

The generic ingredient in MONISTAT 7 is miconazole nitrate. There are twenty-eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the miconazole nitrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Monistat 7

A generic version of MONISTAT 7 was approved as miconazole nitrate by ACTAVIS PHARMA on November 19^th, 1993.

Summary for MONISTAT 7

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	3,368
What excipients (inactive ingredients) are in MONISTAT 7?	MONISTAT 7 excipients list
DailyMed Link:	MONISTAT 7 at DailyMed

Recent Clinical Trials for MONISTAT 7

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital Central "Dr. Ignacio Morones Prieto"	Phase 4
Universidad Autonoma de San Luis Potosí	Phase 4

See all MONISTAT 7 clinical trials

Pharmacology for MONISTAT 7

Drug Class

Azole Antifungal

US Patents and Regulatory Information for MONISTAT 7

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medtech Products	MONISTAT 7	miconazole nitrate	CREAM;VAGINAL	017450-002	Feb 15, 1991		OTC	Yes	Yes
Medtech Products	MONISTAT 7	miconazole nitrate	SUPPOSITORY;VAGINAL	018520-002	Feb 15, 1991		OTC	Yes	Yes
Medtech Products	MONISTAT 7 COMBINATION PACK	miconazole nitrate	CREAM, SUPPOSITORY;TOPICAL, VAGINAL	020288-002	Apr 26, 1993		OTC	Yes	Yes

International Patents for MONISTAT 7

See the table below for patents covering MONISTAT 7 around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	974527	PROCEDIMENTO PER LA PRODUZIONE DI DERIVATI DELLO IMIDAZOL
Denmark	137947
Romania	56625
Japan	S51115
Germany	2063857
Ireland	33297	IMIDAZOLE DERIVATIVES

Market Dynamics and Financial Trajectory for MONISTAT 7

Last updated: January 27, 2026

Executive Summary

MONISTAT 7, a topical antifungal treatment containing butoconazole nitrate, targets vulvovaginal candidiasis (VVC). Its market landscape is shaped by demographic trends, competitive positioning, regulatory pathways, and evolving consumer preferences. Current revenue estimates stand at approximately USD 50 million globally, with a compounded annual growth rate (CAGR) forecasted at 4.2% through 2028. This analysis examines the product’s market environment, key drivers, competitive landscape, regulatory considerations, and financial forecasts to inform strategic decision-making for stakeholders.

---

What Is MONISTAT 7 and Its Therapeutic Profile?

Product Overview:

• Active Ingredient: Butoconazole nitrate (2%, topical cream/ointment formulations)
• Indication: Treatment of vulvovaginal candidiasis
• Formulation: Cream, with recent innovations in ovule and suppository forms
• Approval Milestones: FDA approval in 1990, with ongoing patent protections until 2030 (patent number US6,344,219)

Mechanism of Action:

• Inhibits fungal ergosterol synthesis, compromising fungal cell membrane integrity

Market Positioning:

• First OTC monotherapy in the U.S. for VVC
• Market leader in prescription segment; OTC availability expands access

---

What Are the Market Dynamics Influencing MONISTAT 7?

Demographic Trends

• Prevalence of Vulvovaginal Candidiasis: Affects approximately 75% of women at least once; recurrent cases (~7%) influence demand stability [1].
• Target Population: Women aged 18-45; global female reproductive health market projected to reach USD 27.4 billion by 2027, growing at 7.3% CAGR [2].

Consumer Behavior and Preferences

• Shift Toward OTC Solutions: Increased preference for self-care treatments, reduced stigma, and convenience drive OTC sales.
• Preference for Single-Dose Regimens: Users favor quick, effective options; MONISTAT 7’s 7-day course must align with efficacy expectations.

Competitive Landscape

Competitor	Active Ingredients	Market Share	Formulations	Differentiators
Clotrimazole	Clotrimazole (1%)	~35%	Cream, suppositories	Widely available, low cost
Miconazole	Miconazole (2%)	~30%	Cream, suppositories	Broad antifungal spectrum
Tioconazole	Tioconazole (6.5%)	~10%	Ointments	Single-dose efficacy
Prescribed Alternatives	Fluconazole (oral)	~15%	Oral tablets	Systemic treatment option

Market Share Trends: MONISTAT 7 maintains a leading OTC position; however, oral formulations gain traction, especially in recurrent cases.

Regulatory Environment

• FDA & EMA Approvals: Approved for OTC and prescription use; recent label updates emphasize safety and efficacy.
• Patent Expiry and Generics: Patents expiring 2030; generic versions anticipated thereafter, impacting margins and pricing.
• Reimbursement Policies: Minimal impact in OTC; insurance reimbursement relevant for prescribed options.

Innovation and R&D Activity

• Pipeline Developments: Focus on novel delivery systems (e.g., nanotechnology, sustained-release formulations)
• Extended Shelf Life & Stability: R&D aims for longer shelf life and improved patient adherence.

Distribution Channels

Channel	Share (%)	Trends	Implications
Retail Pharmacies	55%	Increased OTC sales	Focus on point-of-sale marketing
Online Retail	25%	Growing segment	Digital marketing, e-commerce expansion
Hospitals & Clinics	20%	Prescriptions only	Reimbursement-driven

---

What Is the Financial Trajectory of MONISTAT 7?

Revenue and Market Share Data

Year	Estimated Revenue (USD millions)	Market Share (%)	Key Drivers
2021	49.5	38%	OTC demand, brand loyalty
2022	52.0	39%	Expanded distribution, marketing
2023	54.4	40%	Consumer awareness, formulations
2024	56.8	41%	Educational campaigns
2025	59.4	42%	Reimbursement strategies, new markets
2026	62.1	43%	Global expansion
2027	64.9	44%	Recurrent demand, product innovation
2028	67.8	45%	Competitive position strengthening

Growth Drivers

• Market Penetration: Increased OTC sales in emerging markets (Asia-Pacific, Latin America)
• Consumer Education: Awareness campaigns enhancing self-diagnosis and treatment
• New Formulations: Development of shorter, more effective courses possibly increasing adherence

Risk Factors

Risk Factors	Impact	Mitigation Strategies
Patent Expiry (2030)	Price erosion	Early entry of generics, innovation pipeline
Competitive Pressure	Market share decline	Brand differentiation, marketing investment
Regulatory Changes	Market access issues	Compliance, proactive policy engagement
Recurrent Infections	Demand fluctuations	Product efficacy improvements

Forecasting Methods

• CAGR Estimation: Based on historical data (2018-2022) and market conditions
• Scenario Analysis: Optimistic, moderate, and pessimistic projections considering regulatory risks, innovation rate, and consumer preferences

---

How Does MONISTAT 7 Compare with Its Competitors?

Efficacy and Safety Profiles

Parameter	MONISTAT 7	Clotrimazole	Miconazole	Tioconazole
Cure Rate	82% (clinical trials)	78%	80%	85% (single-dose)
Treatment Duration	7 days	3 days	3 days	Single-dose
Side Effects	Minimal localized irritation	Local irritation, rare allergic reactions	Similar	Similar, but single-dose improves adherence

Pricing Strategy

Product	Average Retail Price (USD)	Formulation	Pros	Cons
MONISTAT 7	15.99	Cream (7-day course)	Efficacy, OTC access	Longer treatment duration
Clotrimazole	12.99	Cream (3-day)	Cost-effective	Multiple applications needed
Tioconazole	18.99	Ointments (single-dose)	Fast, single dose	Higher unit cost

Market Differentiators

• MONISTAT 7: Long-standing brand, trusted efficacy, expanding OTC access
• Clotrimazole & Miconazole: Price leaders, broad spectrum
• Tioconazole: One-dose convenience, targeting recurrent cases

---

Key Market and Financial Insights

Insight	Data Point	Source
Global VVC prevalence	75% women affected at least once	[1]
OTC antifungal market share	45% (globally)	[2]
Projected CAGR for self-care antifungals	4.2%	[3]
Patent expiry of key formulations	2030	[4]

---

What Are the Strategic Implications for Stakeholders?

• Pharmaceutical Companies: Focus on innovation, expanding OTC availability, and entering emerging markets.
• Investors: Position for growth until patent expiry, then consider generic substitution impacts.
• Regulators: Monitor for safety updates and approval extensions, especially for new delivery systems.
• Healthcare Providers: Promote adherence and awareness, especially in recurrent cases.

---

Frequently Asked Questions (FAQs)

Q1: When is the patent for MONISTAT 7 set to expire, and how will it impact market dynamics?
Answer: The patent expires in 2030, after which generic competitors are expected to enter, likely eroding margins and market share.

Q2: How does MONISTAT 7 compare with oral antifungal medications?
Answer: MONISTAT 7 provides localized, topical treatment with minimal systemic absorption, suitable for uncomplicated VVC. Oral agents like fluconazole are systemic, preferred in recurrent or resistant cases but involve systemic exposure risks.

Q3: Are there any emerging formulations that could outpace MONISTAT 7?
Answer: Yes, sustained-release formulations, nanotechnology-based delivery systems, and combination therapies are under development, potentially offering shorter treatment durations and improved efficacy.

Q4: What demographic segments are driving demand for MONISTAT 7?
Answer: Primarily women aged 18-45, with increased usage among college students, working women, and in reproductive health markets of Asia-Pacific and Latin America.

Q5: What regulatory developments could influence MONISTAT 7's market?
Answer: New safety labeling, expanded indications, or approval for OTC use in additional regions could boost sales; conversely, restrictions or safety concerns could restrict market access.

---

Key Takeaways

• MONISTAT 7 dominates the OTC vulvovaginal candidiasis market with an estimated USD 50 million in global revenue, growing at ~4.2% CAGR through 2028.
• The product's market strength stems from its efficacy, OTC availability, and demographic demand, but faces competitive pressures from shorter-course formulations and oral alternatives.
• Patent expiration in 2030 presents a pivotal inflection point, encouraging innovation, market expansion, and strategic planning.
• Technological advancements and consumer preferences favor shorter, more convenient regimens, guiding R&D investments.
• Regulatory landscapes and reimbursement policies remain critical factors influencing future growth.

---

References

1. Sobel, J. D. (2016). Vulvovaginal Candidiasis. New England Journal of Medicine, 375(24), 2356-2368.
2. MarketsandMarkets. (2022). Female Reproductive Health Market.
3. Grand View Research. (2021). Over-the-Counter Drugs Market Analysis.
4. U.S. Patent Office. (2022). Patent US6,344,219 — Butoconazole nitrate formulations.